BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry.The full press release is below.Bioresource Technology joins Medix Biochemica GroupMedix Biochemica...
BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create...
BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 - Biosynth Carbosynth...
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information.Download the full 1Q 2022 BroadOak M&A Newsletter....
BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification and phenotypic profiling technologies. Operating Partner Robert Wicke will serve as CEO of Biolog. Bill Snider and Robert Wicke will also serve on the company's Board of Directors. The full...
BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies,...
BroadOak increased its investment in Genomenon, a company that organizes the world's genomic data. The full press release is below. Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data Financing led by Beringea and Spring Mountain Capital to fuel continued growth in pharmaceutical...
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter....
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: "We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland...
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker...
Stay connected
Partner with BroadOak